Nyxthracis (previously Obiltoxaximab SFL) 欧州連合 - クロアチア語 - EMA (European Medicines Agency)

nyxthracis (previously obiltoxaximab sfl)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - imuni serumi i homologna, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.

FLOXILEVO 500 mg/100 mL rastvor za infuziju ボスニア・ヘルツェゴビナ - クロアチア語 - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

floxilevo 500 mg/100 ml rastvor za infuziju

unifarm d.o.o. lukavac - levofloksacin - rastvor za infuziju - 500 mg/100 ml - 1 bočica sa 100 ml rastvora za infuziju sadrži: 500 mg levofloksacina u obliku levofloksacin hemihidrata (5 mg/ml)